A study published in the peer reviewed medical journal "Obesity Research" reports that a twice-daily dose of 250 mg of ForsLean®significantly increased lean body mass and significantly decreased body fat in obese male subjects. This randomized, double-blind, placebo-controlled 12 weeks study examined the effect of forskolin on body composition, testosterone, metabolic rate, and blood pressure in 30 overweight and obese (BMI= 26 kg/m2) men. 15 subjects received ForsLean (250 mg twice daily) and 15 subjects received a matching placebo. ForsLean®administration elicited favorable changes in body composition by significantly decreasing body fat percentage and fat mass as determined by DEXA, compared with the placebo group (p = 0.05). Additionally, forskolin administration resulted in a change in bone mass for the 12-week
Trial compared with the placebo group (p = 0.05). There was a trend toward a significant increase for lean body mass in the forskolin group compared with the placebo group (p = 0.097). Serum free testosterone levels were significantly increased in the forskolin group compared with the placebo group (p = 0.05). The actual change in serum total testosterone concentration was not significantly different among groups, but it increased 16.77 ± 33.77% in the forskolin group compared with a decrease of 1.08 ±18.35% in the placebo group.
The study was performed at the Department of Health Sports and Exercise Sciences, Applied Physiology Laboratory, University of Kansas.
Sabinsa Corporation reminds readers that the beneficial effects of ForsLean are best obtained when the supplement is used in conjunction with a sensible diet and healthy life style measures.
